EICHOR
● Enrolling By Invitation
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
Condition: Breast Cancer Metastatic · Breast Cancer Stage IV · Sponsor: UNICANCER
About this study
After an initial screening phase to identify patients with persistent blood circulating DNA tumors, patients will be enrolled in the treatment phase that was designed as an open-label, multicentre, phase II study, to test the efficacy of trastuzumab deruxtecan in terms of progression-free survival (PFS).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (38)
| Chu Amiens Picardie | Amiens, France | — |
| Clinique de L'Europe Amiens - Cthe | Amiens, France | — |
| Centre Hospitalier D'Auxerre | Auxerre, France | — |
| Sainte Catherine Institut Du Cancer Avignon Provence | Avignon, France | — |
| Centre Hospitalier de la Côte Basque | Bayonne, France | — |
| Centre Hospitalier de Beauvais | Beauvais, France | — |
| Hôpital Simone Veil de Blois | Blois, France | — |
| Centre Hospitalier de Boulogne-Sur-Mer | Boulogne-sur-Mer, France | — |
| Chu de Brest - Hôpital Cavale Blanche | Brest, France | — |
| Clinique Pasteur Lanroze - Cfro - Groupe Vivalto Sante | Brest, France | — |
| Centre Hospitalier William Morey | Chalon-sur-Saône, France | — |
| Centre Hospitalier de Cholet | Cholet, France | — |
+ 26 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06680596